25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Glucocorticoid replacement is essential in patients with primary and secondary adrenal insufficiency, but many patients remain on higher than recommended dose regimens. There is no uniformly accepted method to monitor the dose in individual patients. We have compared cortisol concentrations in plasma, saliva and urine achieved following “physiological” and “stress” doses of hydrocortisone as potential methods for monitoring glucocorticoid replacement.

          Methods

          Cortisol profiles were measured in plasma, saliva and urine following “physiological” (20 mg oral) or “stress” (50 mg intravenous) doses of hydrocortisone in dexamethasone-suppressed healthy subjects (8 in each group), compared to endogenous cortisol levels (12 subjects). Total plasma cortisol was measured half-hourly, and salivary cortisol and urinary cortisol:creatinine ratio were measured hourly from time 0 (between 0830 and 0900) to 5 h. Endogenous plasma corticosteroid-binding globulin (CBG) levels were measured at time 0 and 5 h, and hourly from time 0 to 5 h following administration of oral or intravenous hydrocortisone. Plasma free cortisol was calculated using Coolens’ equation.

          Results

          Plasma, salivary and urine cortisol at 2 h after oral hydrocortisone gave a good indication of peak cortisol concentrations, which were uniformly supraphysiological. Intravenous hydrocortisone administration achieved very high 30 minute cortisol concentrations. Total plasma cortisol correlated significantly with both saliva and urine cortisol after oral and intravenous hydrocortisone ( P <0.0001, correlation coefficient between 0.61 and 0.94). There was no difference in CBG levels across the sampling period.

          Conclusions

          An oral dose of hydrocortisone 20 mg is supraphysiological for routine maintenance, while stress doses above 50 mg 6-hourly would rarely be necessary in managing acute illness. Salivary cortisol and urinary cortisol:creatinine ratio may provide useful alternatives to plasma cortisol measurements to monitor replacement doses in hypoadrenal patients.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: not found
          • Article: not found

          Adrenal insufficiency.

          W Oelkers (1996)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.

            The adverse metabolic effects of prescribed and endogenous glucocorticoid (GC) excess, Cushing syndrome, create a significant health burden. We found that tissue regeneration of GCs by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), rather than circulating delivery, is critical to developing the phenotype of GC excess; 11β-HSD1 KO mice with circulating GC excess are protected from the glucose intolerance, hyperinsulinemia, hepatic steatosis, adiposity, hypertension, myopathy, and dermal atrophy of Cushing syndrome. Whereas liver-specific 11β-HSD1 KO mice developed a full Cushingoid phenotype, adipose-specific 11β-HSD1 KO mice were protected from hepatic steatosis and circulating fatty acid excess. These data challenge our current view of GC action, demonstrating 11β-HSD1, particularly in adipose tissue, is key to the development of the adverse metabolic profile associated with circulating GC excess, offering 11β-HSD1 inhibition as a previously unidentified approach to treat Cushing syndrome.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Modified-release hydrocortisone to provide circadian cortisol profiles.

              Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss of this rhythm is associated with metabolic abnormalities, fatigue, and poor quality of life. Conventional glucocorticoid replacement cannot replicate this rhythm. Our objectives were to define key variables of physiological cortisol rhythm, and by pharmacokinetic modeling test whether modified-release hydrocortisone (MR-HC) can provide circadian cortisol profiles. The study was performed at a Clinical Research Facility. Using data from a cross-sectional study in healthy reference subjects (n = 33), we defined parameters for the cortisol rhythm. We then tested MR-HC against immediate-release hydrocortisone in healthy volunteers (n = 28) in an open-label, randomized, single-dose, cross-over study. We compared profiles with physiological cortisol levels, and modeled an optimal treatment regimen. The key variables in the physiological cortisol profile included: peak 15.5 microg/dl (95% reference range 11.7-20.6), acrophase 0832 h (95% confidence interval 0759-0905), nadir less than 2 microg/dl (95% reference range 1.5-2.5), time of nadir 0018 h (95% confidence interval 2339-0058), and quiescent phase (below the mesor) 1943-0531 h. MR-HC 15 mg demonstrated delayed and sustained release with a mean (sem) maximum observed concentration of 16.6 (1.4) microg/dl at 7.41 (0.57) h after drug. Bioavailability of MR-HC 5, 10, and 15 mg was 100, 79, and 86% that of immediate-release hydrocortisone. Modeling suggested that MR-HC 15-20 mg at 2300 h and 10 mg at 0700 h could reproduce physiological cortisol levels. By defining circadian rhythms and using modern formulation technology, it is possible to allow a more physiological circadian replacement of cortisol.
                Bookmark

                Author and article information

                Contributors
                carolinejung@yahoo.com
                mrsanto@bigpond.net.au
                Hanh.Nguyen@mps.com.au
                Jui.Ho@health.sa.gov.au
                john.lewis@cdhb.govt.nz
                David.Torpy@health.sa.gov.au
                warrick.inder@health.qld.gov.au
                Journal
                BMC Endocr Disord
                BMC Endocr Disord
                BMC Endocrine Disorders
                BioMed Central (London )
                1472-6823
                26 November 2014
                26 November 2014
                2014
                : 14
                : 1
                : 91
                Affiliations
                [ ]Department of Endocrinology and Diabetes, St Vincent’s Hospital, Melbourne, VIC Australia
                [ ]School of Medicine, The University of Melbourne, Melbourne, VIC Australia
                [ ]Department of Biochemistry, Melbourne Pathology, Melbourne, VIC Australia
                [ ]Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia Australia
                [ ]Steroid & Immunobiochemistry Laboratory, Canterbury Health Laboratories, Christchurch, New Zealand
                [ ]Endocrine Research, Hanson Institute, Adelaide, South Australia Australia
                [ ]School of Medicine, The University of Adelaide, Adelaide, South Australia Australia
                [ ]Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD Australia
                [ ]School of Medicine, The University of Queensland, Brisbane, QLD Australia
                Article
                297
                10.1186/1472-6823-14-91
                4280712
                25425285
                d16a3ace-e903-442f-9b80-2763216f798a
                © Jung et al.; licensee BioMed Central Ltd. 2014

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 September 2014
                : 18 November 2014
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2014

                Endocrinology & Diabetes
                adrenal cortex,hpa axis (hypothalamic-pituitary-adrenal),cortisol,hydrocortisone

                Comments

                Comment on this article